For decades, aging has been treated as an inevitable backdrop to disease rather than a modifiable biological process. That framing is now under serious pressure. A comprehensive review in Cell Reports Medicine maps the emerging landscape of gene-based interventions designed not merely to treat age-related conditions one at a time, but to alter the upstream molecular machinery that drives biological aging itself — a shift with profound implications for how medicine approaches the second half of the human lifespan.
The review systematically examines three converging therapeutic fronts: genome editing technologies that can correct or silence aging-accelerating genetic variants, RNA modulation strategies that fine-tune gene expression without altering the underlying DNA sequence, and epigenetic reprogramming approaches — most notably partial cellular reprogramming using Yamanaka factors — that aim to reset the epigenetic age of tissues. Particular attention is paid to well-characterized aging-regulatory pathways including telomere maintenance mechanisms, stress-response networks such as the integrated stress response and heat shock pathways, and epigenetic drift that accumulates across the lifespan. Safety considerations, including off-target editing effects and oncogenic risk from reprogramming, are addressed within translational frameworks intended to guide clinical development.
This synthesis arrives at a moment when the geroprotection field is maturing rapidly but remains largely pre-clinical. Most landmark results — including life extension via telomerase gene delivery or partial reprogramming in animal models — have not yet translated into human efficacy data, a limitation the review implicitly acknowledges by foregrounding mechanistic insights over clinical outcomes. For health-conscious adults, the practical horizon remains years away, but the conceptual architecture being built here matters: it positions aging itself as a treatable condition rather than a fixed biological sentence. The review is best understood as an expert navigation tool for researchers and informed readers tracking where translational geroscience is heading, rather than announcing imminent clinical breakthroughs. Incremental in its immediate impact, but strategically important for the field's direction.
